Corporate Investors Boost M&A Step-Ups, But Not IPOs
This article was originally published in Start Up
Corporate venture capital groups have made an impact on life science investing in recent years, but when it comes to going public, the biotechs they back aren’t seeing an extra boost.
You may also be interested in...
Corporate Venture Eyes The Early Stage
In our second annual Life Science Venture Survey, VCs paid their respects to the importance of corporate investors right now. For their part, corporate investors, many from long-established programs, said they are bullish about making more bets in early-stage companies.
Corporate VC Backing Influences Private M&A Step-Ups
New data show that including one or more corporate venture investors in a syndicate actually translates into a higher median step-up valuation.
RNA Medicines: Advancements Leading To Investments
Improvements in generating, purifying, and delivering RNA material, as well as addressing challenges with degradation by enzymes, have made the RNA class more attractive to drug developers.